A landmark population-based study spanning 2006-2020 in Stockholm, Sweden, reveals that biochemically confirmed primary hyperparathyroidism incidence increased by 52% while only half of affected patients received clinical diagnosis, highlighting significant diagnostic gaps in this treatable endocrine disorder.